Combredet Chantal, Labrousse Valérie, Mollet Lucile, Lorin Clarisse, Delebecque Frédéric, Hurtrel Bruno, McClure Harold, Feinberg Mark B, Brahic Michel, Tangy Frédéric
Unité des Virus Lents, CNRS URA 1930, Paris, France.
J Virol. 2003 Nov;77(21):11546-54. doi: 10.1128/jvi.77.21.11546-11554.2003.
Live attenuated RNA viruses make highly efficient vaccines. Among them, measles virus (MV) vaccine has been given to a very large number of children and has been shown to be highly efficacious and safe. Therefore, this vaccine might be a very promising vector to immunize children against both measles and other infectious agents, such as human immunodeficiency virus. A vector was previously derived from the Edmonston B strain of MV, a vaccine strain abandoned 25 years ago. Sequence analysis revealed that the genome of this vector diverges from Edmonston B by 10 amino acid substitutions not related to any Edmonston subgroup. Here we describe an infectious cDNA for the Schwarz/Moraten strain, a widely used MV vaccine. This cDNA was constructed from a batch of commercial vaccine. The extremities of the cDNA were engineered in order to maximize virus yield during rescue. A previously described helper cell-based rescue system was adapted by cocultivating transfected cells on primary chicken embryo fibroblasts, the cells used to produce the Schwarz/Moraten vaccine. After two passages the sequence of the rescued virus was identical to that of the cDNA and of the published Schwarz/Moraten sequence. Two additional transcription units were introduced in the cDNA for cloning foreign genetic material. The immunogenicity of rescued virus was studied in macaques and in mice transgenic for the CD46 MV receptor. Antibody titers and T-cell responses (ELISpot) in animals inoculated with low doses of rescued virus were identical to those obtained with commercial Schwarz MV vaccine. In contrast, the immunogenicity of the previously described Edmonston B strain-derived MV clone was much lower. This new molecular clone will allow for the production of MV vaccine without having to rely on seed stocks. The additional transcription units allow expressing heterologous antigens, thereby providing polyvalent vaccines based on an approved, safe, and efficient MV vaccine strain that is used worldwide.
减毒活RNA病毒可制成高效疫苗。其中,麻疹病毒(MV)疫苗已接种给大量儿童,且已证明其高效且安全。因此,这种疫苗可能是一种非常有前景的载体,可用于使儿童同时免疫麻疹和其他感染因子,如人类免疫缺陷病毒。一种载体先前源自MV的埃德蒙斯顿B株,这是一种25年前被弃用的疫苗株。序列分析表明,该载体的基因组与埃德蒙斯顿B株有10个氨基酸替换不同,这些替换与任何埃德蒙斯顿亚组均无关。在此,我们描述了一种针对施瓦茨/莫拉滕株的感染性cDNA,这是一种广泛使用的MV疫苗。该cDNA由一批商业疫苗构建而成。对cDNA的末端进行了工程改造,以在拯救过程中使病毒产量最大化。通过将转染细胞与原代鸡胚成纤维细胞共培养,对先前描述的基于辅助细胞的拯救系统进行了改进,原代鸡胚成纤维细胞是用于生产施瓦茨/莫拉滕疫苗的细胞。经过两轮传代后,拯救出的病毒序列与cDNA以及已发表的施瓦茨/莫拉滕序列相同。在cDNA中引入了另外两个转录单元,用于克隆外源遗传物质。在猕猴和表达CD46 MV受体的转基因小鼠中研究了拯救出的病毒的免疫原性。用低剂量拯救出的病毒接种的动物中的抗体滴度和T细胞反应(ELISpot)与使用商业施瓦茨MV疫苗所获得的结果相同。相比之下,先前描述的源自埃德蒙斯顿B株的MV克隆的免疫原性要低得多。这种新的分子克隆将使得无需依赖种子毒株就能生产MV疫苗。额外的转录单元允许表达异源抗原,从而基于一种在全球范围内使用的经批准、安全且高效的MV疫苗株提供多价疫苗。